Report : Europe ELISA Diagnostics Tests Market Forecast to 2030 - Regional Analysis - by Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), and End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others)
At 6.6% CAGR, the Europe ELISA Diagnostics Tests Market is Speculated to be worth US$ 534.65 million by 2030, says Business Market Insights
According to Business Market Insights research, the Europe ELISA diagnostics tests market was valued at US$ 319.59 million in 2022 and is expected to reach US$ 534.65 million by 2030, registering a CAGR of 6.6% from 2022 to 2030. Innovative product launches and advancements in ELISA-based procedures are among the critical factors attributed to the Europe ELISA diagnostics tests market expansion.
ELISA is one of the most popular immunoassay tests owing to its various advantages such as flexibility, sensitivity, and easy-to-use features. Also, low cost of ELISA test kit and multifaceted applicability associated with high-throughput testing make it an ideal solution for various research and IVD requirements. With low-cost applicability, product innovations in the test kits enhance the demand for human and animal research. Also, manufacturers focus on developing ELISA test kits with in-house facilities.
Innovative Research company sells a wide range of ELISA kits with selectivity to a broad range in identifying coagulants, species, and antibodies. "Human Factor IX Kit" is one such example manufactured by Innovative Research. The human coagulation Factor IX antigen assay is intended for the quantitative determination of total Factor IX antigen in human plasma. The kit is recommended to use only for research purposes, and reagents can be utilized for up to 96 clinical tests. Additionally, innovative product launches for ELISA tests by the manufacturers amid the COVID-19 pandemic accelerate the adoption of ELISA testing among humans. In December 2022, Pictor Limited announced a new product launch of the "PictArray SARS-CoV-2 Antibody Test," which has demonstrated real clinical utility intended for patients and doctors. The new product detects the infection associated with the COVID-19 virus, and the clinical results produced assist the patients and doctors in treating and managing SARS-CoV-2 infection. Launches of innovative ELISA test kits by manufacturers are expected to provide effective clinical results for diagnosing varied infections associated with different types of species with low cost and multifaceted applications. Thus, innovative product launches would provide lucrative opportunities for manufacturers in the long run.
On the contrary, incidents of product recalls hamper the growth of Europe ELISA diagnostics tests market.
Based on adoption, the Europe ELISA diagnostics tests market is bifurcated into human and veterinary. The human segment held 65.5% market share in 2022, amassing US$ 209.19 million. It is projected to garner US$ 362.51 million by 2030 to expand at 7.1% CAGR during 2022-2030.
In terms of test type, the Europe ELISA diagnostics tests market is categorized into sandwich ELISA, indirect ELISA, competitive ELISA, and multiple & portable ELISA. The indirect ELISA segment held 35.4% share of Europe ELISA diagnostics tests market in 2022, amassing US$ 112.99 million. It is projected to garner US$ 207.28 million by 2030 to expand at 7.9% CAGR during 2022-2030.
Based on application, the Europe ELISA diagnostics tests market is categorized into autoimmune diseases, infectious diseases, cancer diagnosis, protein quantification, and others. The infectious diseases segment held 41.3% share of Europe ELISA diagnostics tests market in 2022, amassing US$ 131.92 million. It is projected to garner US$ 237.45 million by 2030 to expand at 7.6% CAGR during 2022-2030.
By end user, the Europe ELISA diagnostics tests market is categorized into hospitals & diagnostic centers, pharmaceutical & biotechnology companies, veterinary hospitals & diagnostic laboratories, and others. The hospitals & diagnostic centers segment held 40.4% share of Europe ELISA diagnostics tests market in 2022, amassing US$ 129.09 million. It is projected to garner US$ 230.91 million by 2030 to expand at 7.5% CAGR during 2022-2030.
Based on country, the Europe ELISA diagnostics tests market has been categorized into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 29.5% share of Europe ELISA diagnostics tests market in 2022. It was assessed at US$ 94.31 million in 2022 and is likely to hit US$ 188.46 million by 2030, exhibiting a CAGR of 9.0% during 2022-2030.
Key players operating in the Europe ELISA diagnostics tests market are Bio-Rad Laboratories Inc., Idexx Laboratories Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corp., Innovative Diagnostics SAS, DiaSorin SpA, Elabscience Biotechnology Inc., and Bio-Techne Corp., among others.
- In Oct 2021, Roche launches comprehensive genomic profiling kit to expand access to personalized cancer research.
- In Aug 2021, Danaher Completes Acquisition of Aldevron.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com